Ivan V. Trukhin

Ivan V. Trukhin

Auto-generated profile, based on publicly available information

Ivan V. Trukhin

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2019 in Diabetes mellitus
Verified
Journal Article
Open access
PDF file
NPNina Petunina
Nina Petunina
ITIvan Trukhin
Ivan Trukhin
LTLiubov Trukhina
Liubov Trukhina
ZSZhanna Sizova
Zhanna Sizova
VZValeria Zakharova
Valeria Zakharova
Diabetes mellitus (DM) and heart failure (HF) are frequent comorbidities with a bidirectional relationship. Patients with HF have increased risk of developing DM, and those with DM are at greater risk of developing HF. HF does not fit clearly into the microangiopathy and macroangiopathy groups. It is known that coronary artery disease and arterial hypertension are the major causes of HF; however, it has been shown that DM can trigger functional and structural abnormalities in the myocardium via diabetic cardiomyopathy, a condition with either restrictive or dilated phenotype. While HF treatment is equally effective and safe in patients with and without DM, this statement is not applicable for antidiabetic treatment. Several antidiabetic drugs, such as rosiglitazone, pioglitazone and saxagliptin increase the risk of hospitalisation for HF, therefore these antidiabetic drugs are contraindicated in patients with DM and HF or patients at risk of developing HF. Despite a large number of clinical evidence, uncertainty about the safety of antidiabetic drugs in patients with HF always exists. In this review, the issues of DM treatment in patients with HF are addressed in detail.

4 December 2019 in Annals of the Russian academy of medical sciences
Verified
Journal Article
Open access
ITIvan V. Trukhin
Ivan V. Trukhin
DSDmitrij Yu. Schekochikhin
Dmitrij Yu. Schekochikhin
NNNina Novikova
Nina Novikova
AAAnna S. Akselrod
Anna S. Akselrod
ASAbram L. Syrkin
Abram L. Syrkin
EPEkaterina S. Pershina
Ekaterina S. Pershina
AL cardiac amyloidosis is a relatively rare disorder that belongs to the group of infiltrative cardiomyopathies. Diagnosis of primary amyloidosis is challenging due to many unspecific symptoms and sings, which often leads to late diagnosis when treatment options are limited. Primary amyloidosis particularly needs to be excluded in patients with heart failure with preserved ejection fraction. Therapy in cardiac amyloidosis has to main vectors: 1) chemotherapy to eliminate amyloidogenic plasmatic cells 2) heart failure treatment. The main challenge for cardiologists is to support hemodynamics until response to chemotherapy occurs. In the article the issue of diagnostics, risk stratification and treatment of primary cardiac amyloidosis is addressed.